Treatment Advances for Challenging Patients with Type 2 Diabetes: The Role of Emerging Insulin Combinations

In patients with type 2 diabetes mellitus (T2DM), improving adherence and outcomes with conventionally available insulin products is challenging as these agents can fail to overcome many of the barriers associated with insulin therapy, such as fear of hypoglycemia, potential for weight gain, and concerns regarding the injection process and frequency. Newly available insulin fixed-ratio combination products, such as insulin/glucagon-like peptide receptor agonists (GLP-1 RAs), offer improved hemoglobin A1c control with less potential for hypoglycemia and weight gain and less stringent injection requirements. Such products have demonstrated positive effects in patients’ fasting and postprandial plasma glucose. In this archived symposium activity, expert faculty will review the current safety and efficacy data of these therapies, the roles they play in clinical management of patients with T2DM, and practical considerations through clinical case studies and discussion.


Please Note: this course is housed on Free CME. Upon selecting 'Take Course,' you will be redirected to Free CME to complete the activity.

Target Audience

This activity is designed for endocrinology care providers and other healthcare providers who manage patients with T2DM. There are no prerequisites.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • EVALUATE evidence supporting the use of GLP-1RA/insulin combinations as a means to overcome barriers to achieving glycemic control.
  • ASSESS the potential role of insulin/GLP-1RA combination therapies in management, particularly as it relates to more complicated T2DM patients.
  • IDENTIFY clinical situations relevant to endocrinology practices in which the use of a GLP-1RA/insulin combination may be beneficial.
Additional information
Available for MOC Points?: 
No
Practice Area: 
Diabetes
Course summary
Available credit: 
  • 1.75 AMA
  • 1.75 Attendance
Course opens: 
01/15/2018
Course expires: 
01/15/2019
Cost:
$0.00

Lawrence Blonde, MD, FACP, MACE (Chairperson)

Director, Ochsner Diabetes Clinical Research Unit
Frank Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, Louisiana

Martin J. Abrahamson, MD

Associate Professor of Medicine
Harvard Medical School
Director Division of CME
Department of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Alan J. Garber, MD, PhD, MACE

Professor
Departments of Medicine, Biochemistry and Molecular Biology, and Molecular and Cellular Biology
Baylor College of Medicine
Houston, Texas
Past President, American Association of Clinical Endocrinologists and
the American College of Endocrinology
Senior Editor, Diabetes Obesity and Metabolism

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.75 AMA
  • 1.75 Attendance

Accreditation Period

Course opens: 
01/15/2018
Course expires: 
01/15/2019

Price

Cost:
$0.00
Please login or register to take this course.